Trial Profile
A Long-Term Clinical Study of TS-071 as Combination Therapy With GLP-1 Receptor Agonist in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2018
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.